Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Instagram
  • Listen to CMAJ podcasts
News

FDA ban of generic oxycodone calls into question Health Canada’s approval

Adam Miller
CMAJ June 11, 2013 185 (9) E381-E382; DOI: https://doi.org/10.1503/cmaj.109-4476
Adam Miller
CMAJ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

Health Canada is facing increased criticism for its approval of generic oxycodone after the US Food and Drug Administration (FDA) decided to ban generic versions of the drug that has been widely abused across North America.

The FDA made its landmark ruling just days before Purdue Pharma’s patent on the original time-release formula of OxyContin was set to expire Apr. 23.

The original formulations of the drug, including OxyContin and its generic, “poses an increased potential for abuse by certain routes of administration,” says Morgan Liscinsky, a spokesperson for the FDA. “The agency has therefore determined that the benefits of original OxyContin no longer outweigh its risks.”

In April 2010, the FDA approved OxyNEO as the standard replacement for OxyContin, because the physical and chemical properties of it make it harder to abuse either by injection or snorting.

Despite the FDA’s latest decision not to allow the generic version of OxyContin, Health Canada says it has no plans to revisit the issue and is satisfied with its decision, which it says is based purely on scientific evidence.

Federal Health Minister Leona Aglukkaq “chose to not politically interfere and we still believe that that’s the right decision because politicians shouldn’t be deciding, in our view, which drugs get on the market and which ones don’t — that should be based on science,” says Steve Outhouse, Aglukkaq’s spokesperson.

“Ours is a scientific-based approach that looks at … whether the benefits outweigh the risks,” said Outhouse.

“Our minister felt it was the right approach, and the Americans feel that their approach is the right one,” says Outhouse. “Ultimately what’s happening here is that all sides agree it’s an issue and they’re just looking for ways to deal with it.”

Figure

The original OxyContin, which was relatively easy to snort or inject, was widely abused.

Image courtesy of © 2013 Thinkstock

“The Americans have chosen to ban it outright and allow the more costly version of OxyNEO to be sold. We’ve heard from patients that that doesn’t work for them as well. And so we’re all trying to deal with the issue.”

Aglukkaq made the controversial decision to approve the manufacture of generic forms of oxycodone last November, despite urgings from every provincial and territorial health minister to, at the very least, delay the decision until more research had been conducted.

The federal government’s decision not to revisit the approval is not sitting well with the Ontario minister of health and a prescription drug abuse expert.

“I think the science supports the banning of [the generic version],” says Ontario Health Minister Deb Matthews. “I think the evidence is absolutely clear that oxycodone addiction is a very, very serious problem throughout Canada … and I applaud [the FDA’s] decision.”

She says the FDA likely looked at the complete profile of the drug including its safety and whether people use it as prescribed. “And that’s the perspective I wished the Canadian federal government had taken.”

Matthews said she will continue to urge Health Canada to reconsider its decision. At a recent meeting of Canadian health ministers, the issue arose spontaneously “and people feel as passionately now as they did [in November]. And the greatest passion comes from the health ministers in the territories.”

Dr. Irfan Dhalla, a member of the national advisory council that recently released a strategy for prescription drug abuse and misuse and a physician at St. Michael’s Hospital in Toronto, Ontario, agrees with Matthews.

“The FDA made the right call. I can’t understand why Health Canada wouldn’t want to look at the evidence the FDA reviewed and reconsider,” Dhalla writes in an email. “The FDA is signaling, both through its decision and through its admirably transparent communications, that it wants all opioids to be tamper-resistant in the near future. Health Canada should be moving in the same direction.”

Instead, Health Canada is touting its decision to approve generic oxycodone as a success, just four months after the decision was made.

Outhouse says although it’s still early in the process, there are positive indicators that it’s not been prescribed as often as it has been in the past.

“It’s down to very low levels which seems to … back up the minister’s position. … [It] makes it available for people who need it … to access it legally and to … pay a better price than they would if they had to go through brand name options.”

Dhalla thinks it’s too early to assess the health effects of allowing generic oxycodone onto the market in Canada.

“Fortunately, I think the vast majority of physicians are not prescribing generic OxyContin. But some probably are, and I think it’s highly likely that some people will probably die as a result. Health Canada should have made the right decision last year. But better late than never.”

PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 185 (9)
CMAJ
Vol. 185, Issue 9
11 Jun 2013
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
FDA ban of generic oxycodone calls into question Health Canada’s approval
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
FDA ban of generic oxycodone calls into question Health Canada’s approval
Adam Miller
CMAJ Jun 2013, 185 (9) E381-E382; DOI: 10.1503/cmaj.109-4476

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
FDA ban of generic oxycodone calls into question Health Canada’s approval
Adam Miller
CMAJ Jun 2013, 185 (9) E381-E382; DOI: 10.1503/cmaj.109-4476
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Saying goodbye to CMAJ News
  • National survey highlights worsening primary care access
  • How Canadian hospitals are decreasing carbon emissions
Show more News

Similar Articles

Collections

  • Topics
    • Addiction medicine
    • Global health

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected]

CMA Civility, Accessibility, Privacy

 

Powered by HighWire